• Under BC Partners’ active ownership, Synthon has expanded rapidly, more than doubling EBITDA
• Transaction maintains BC Partners’ momentum in realisations, generating c.€13bn in monetisations over the past 18 months, and c.€9bn in 2024

BC Partners, a leading international investment firm, and Goldman Sachs Alternatives today announced that they have entered into an agreement under which the Private Equity business at Goldman Sachs Alternatives will acquire a majority stake in Synthon, a leading international pharmaceutical company, from funds advised by BC Partners. BC Partners will retain a minority stake in Synthon to support future growth. Terms of the transaction were not disclosed.

BC Partners acquired its majority stake in Synthon from the company’s founders in 2019 through a bilateral transaction. Leveraging its significant pharmaceutical and generic drugs sector expertise – gained through prior investments such as Pharmathen – BC Partners, together with the management, was able to drive significant organic growth and geographic expansion with a focus on commercial excellence, R&D, technology differentiation, and operational excellence. Since the initial investment five years ago, Synthon has more than doubled EBITDA and cemented its leading position in the sector.

Mark Hersee, Partner and Co-Head of Healthcare at BC Partners, said: “Synthon is a fantastic business and it has been a pleasure to partner with Anish and the rest of the team since we first invested in 2019. During our ownership we have heavily invested in additional complex technologies, expanded manufacturing capabilities, and strengthened the team to enter new geographies, all building on the great work of the Founders. We see great potential for Synthon, and it is for that reason we are delighted to partner with the Goldman Sachs Alternatives team in continuing to grow and expand the business.”

Anish Mehta, Synthon CEO, said: “The journey over the last few years with BC Partners has been an exciting one – and we thank them for their support and collaboration. They have been an important strategic partner for Synthon and the management team as we transformed the business into a best-in-class, high-growth development company. Working together to identify opportunities, we made significant strategic investments to accelerate our growth, improve our operational network and advance our R&D platforms and capabilities for increasingly complex generics. As we look to the next phase of our growth journey, we are excited to be partnering with Goldman Sachs Alternatives, and continuing to work with BC. The network, expertise and combined resources of both firms will be a key enabler for our continued growth and success in the coming years.”

Adam Dawson, Managing Director and Global Co-Head of Healthcare Private Equity at Goldman Sachs Alternatives, said: “We look forward to collaborating with management to drive value creation through product and pipeline development and operational excellence initiatives as well as execute on our joint vision to strengthen Synthon’s global impact. Synthon’s track record and expertise in complex drug development, intellectual property formation, and manufacturing position it well to capture the secular growth of generic medicines and increase access to affordable medicines for patients globally.”

Michael Bruun, Partner and Global Co-Head of Private Equity at Goldman Sachs Alternatives, said: “We have keenly followed Synthon’s trajectory for many years and see tremendous opportunities for future growth. We are thrilled to partner with BC Partners and Synthon’s management. We look forward to supporting management with the Goldman Sachs network and value acceleration resources.”

With this transaction, BC Partners has generated c.€13bn in proceeds over the past 18 months, delivering c.€9bn in 2024 alone. These monetisations demonstrate the high quality of businesses and exit optionality which underpin BC Partners’ portfolio and position in the market. Recent monetisations include the exit of Forno d’Asolo Group, IMA Industria Macchine Automatiche SpA, Presidio and GardaWorld as well as the successful listing of Springer Nature on the Frankfurt Exchange in October 2024.

BC Partners was advised by Rothschild & Co, Barclays, Latham & Watkins, and PwC.

The transaction, which is subject to customary closing conditions, is expected to close in Q2 2025.

–ENDS —

About BC Partners BC Partners is a leading investment firm with circa €40 billion in assets under management across private equity, private debt, and real estate strategies. Established in 1986, BC Partners has played an active role for over three decades in developing the European buy-out market. Today BC Partners integrated transatlantic investment teams work from offices in Europe and North America and are aligned across our four core sectors: TMT, Healthcare, Services & Industrials, and Consumer. Since its foundation, BC Partners has completed over 128 private equity investments in companies with a total enterprise value of over €160 billion and is currently investing its eleventh private equity buyout fund. For further information, please visit https://www.bcpartners.com/

About Synthon Synthon is a vertically integrated, global leader in the development and manufacturing of complex generics. For over three decades, the Company has established a proven track record of launching IP differentiated, complex products at market formation. Synthon has a global footprint with direct presence in eight countries, including four R&D labs as well as four manufacturing sites located in Spain, Czech Republic, Argentina, and Chile. The Company is headquartered in the Netherlands and has approximately 1,600 employees. With a portfolio of over 70 molecules, and diversified base of more than 200 customers serving around 100 countries, Synthon is delivering on its mission of Enabling Affordable Medicines Globally. Follow us on LinkedIn. For further information, please visit https://www.synthon.com/

We are excited to announce that Polaris has signed an agreement to acquire a majority stake in Salfarm, a Danish Animal Pharma player, with the aim of establishing a leading player in the Nordic Animal Health market. Shortly after the transaction, Salfarm has, in collaboration with Polaris, acquired the Finnish veterinary pharma player, FaunaPharma, strengthening Salfarm’s presence in Finland.

Salfarm was founded in 1979 and has grown to become a leading Danish player within animal pharmaceuticals with a presence throughout the Nordics delivering a +10% annual growth rate over a ten-year period. Headquartered in Kolding, Denmark, Salfarm owns subsidiaries in Sweden, Norway, and as of recently Finland, following the acquisition of FaunaPharma.

“We are very impressed by the journey that Salfarm has undergone. Today, Salfarm is a leading Danish player within animal pharmaceuticals, recognized by both suppliers and customers as a key partner and market expert in the Nordic region. Building on the strong team at Salfarm and their deep competencies and relationships, the ambition is to strengthen and grow Salfarm’s position outside of Denmark and establish a leading player in the Nordic market. The acquisition of FaunaPharma has been a first step on this journey,” says Simon Damkjær Wille, Partner at Polaris.

Please see the following press release:

English
Danish

For further information, please contact:
Simon Damkjær Wille, Partner
Phone: +45 4220 9639
Mail: sw@polarisequity.dk

Camilla Ringsted, Associate Director
Phone: +45 2968 6909
Mail: cri@polarisequity.dk

(Hong Kong, 2 April 2024) – Trustar Capital (the private equity affiliate of CITIC Capital Holdings Limited)
is pleased to announce the successful completion of the acquisition of leading throat healthcare
company Guilong Pharmaceutical (Anhui) Co., Ltd. (“Guilong Pharmaceutical”, or the “Company”) via its
China buyout fund. This acquisition marks a significant milestone in Trustar Capital’s investment strategy
in the OTC pharmaceutical and wellness industry.

Established in 1989, Guilong Pharmaceutical has a rich history of over 30 years. Guided by the mission
of “Inheriting the Essence of Chinese Medicine, Promoting Public Health”, Guilong Pharmaceutical has
continuously pursued research and innovation to enrich its product portfolio, covering both the OTC
pharmaceutical and the larger wellness sector. Over the years, the company has successfully built two
well-known brands, Guilong ( ) and Manyanshuning ( ), offering a comprehensive selection
of solutions for throat problems spanning from mild to severe conditions. Additionally, Guilong
Pharmaceutical has expanded its product line into the broader wellness sector, providing consumers
with a diverse selection of products for throat health and related areas.

With the increasing demand for medical health, the OTC pharmaceutical and wellness industry in China
has a promising outlook. OTC pharmaceuticals play a crucial role in improving treatment accessibility
and reducing healthcare costs. In recent years, there has been a significant surge in China’s self-care and
self-medication markets, bolstered by the extensive support from national policies. Furthermore, factors
such as an aging population, heightened public health awareness, tech innovation, and pervasive
healthcare reform will continue to drive steady growth in the Chinese OTC pharmaceutical market.
According to IQVIA, a leading global healthcare service provider, the market size of OTC sector will
exceed RMB300 billion by 2025.

Feng DAI, general manager of Guilong Pharmaceutical, said: “Since its establishment over 30 years ago,
Guilong Pharmaceutical has consistently focused on the needs of consumers, laid great emphasis on
product efficacy and quality management, and regarded product competitiveness as a backbone of the
brand, hence has built a leading reputation in the throat health sector. In the future, under the support of
Trustar Capital, Guilong Pharmaceutical will actively expand the treatment offerings, enhance product
portfolio, and improve omnichannel presence to strengthen our leading position in the OTC
pharmaceutical markets.”

Yan ZHAO, Partner of Trustar Capital, said: “We are optimistic about the future of China’s OTC
pharmaceuticals industry. We highly recognize Guilong’s excellent reputation in the market and their
iconic brand and are excited to work with the outstanding and energetic management team led by general
manager DAI Feng. Looking ahead, we aim to utilize our resources and post-investment experience to
further empower the company. Additionally, we plan to leverage our M&A expertise and network to
expand Guilong Pharmaceutical’s product line and treatment offerings, driving sustainable growth going
forward.”

Trustar Capital has significant investment experience in the healthcare sector, focusing on
comprehensively and continuously integrating resources and expanding the industry, and has
established a rich ecosystem of portfolio enterprises, including Harbin Pharmaceutical Group, GNC,
Taibang Biologic Group, Jissbon, Genertec Universal Medical, Hygeia Healthcare, Genesis MedTech,
MedAlliance and other high-quality enterprises. This acquisition of Guilong Pharmaceutical aligns
perfectly with Trustar Capital’s buyout investment strategy. It also showcases Trustar Capital’s deep
experience and strong capabilities when it comes to multinational corporations carving out their Chinese
businesses. Moving forward, Trustar Capital will remain focused on mergers and integration within the
OTC pharmaceutical and wellness space and create long-term value by building out a complete suite of
public health services over the long run.

About Trustar Capital
Trustar Capital, the private equity affiliate of CITIC Capital Holdings Limited, focuses on control buyout
opportunities globally and has completed around 100 investments since inception across China, Japan,
U.S., Europe, etc. Trustar Capital currently manages USD8.7 billion of committed capital. For more
information, please visit http://www.trustarcapital.com/.
Founded in 2002, CITIC Capital Holdings Limited is an alternative investment management and advisory
company. The firm manages over USD16 billion of capital across 100 funds and investment products
through its multiple asset class platform covering private equity, real estate, structured investment &
finance, and asset management. CITIC Capital has over 290 portfolio companies that span 11 sectors
and employ over 500,000 people around the world.

For media enquiries, please contact:
Cindy TAM
Director, Corporate Relations
CITIC Capital Holdings Limited
Tel: +852 3710 6813
cindytam@citiccapital.com
Irene GAO
Senior Associate, Corporate Relations
CITIC Capital Holdings Limited
Tel: +852 3710 6814
irenegao@citiccapital.com

• The joint investment will foster future growth and innovation in the near-and long-term
• During Nordic Capital’s ownership to date, Advanz Pharma has transformed into a leading European specialty pharmaceutical platform

Ontario Teachers’ Pension Plan Board (“Ontario Teachers’”), a leading global institutional investor, and Nordic Capital, one of the most active and experienced investors in healthcare globally, have agreed to jointly invest in Advanz Pharma (“Advanz”), a global pharmaceutical company, to support Advanz’s development and further fuel its strong growth potential in the years to come.

Advanz is a global pharmaceutical company with a strategic focus on specialty, hospital and rare diseases pharmaceuticals. It has commercial sales in more than 90 countries globally with a direct presence in key countries in Europe, the US, Canada, and Australia, and a Centre of Excellence for business support in Mumbai, India.

Advanz’s product portfolio and pipeline comprise innovative medicines, specialty generics & biosimilars and originator brands. Advanz addresses a broad range of therapeutic areas, including hepatology, gastroenterology, anti-infectives, critical care, endocrinology, CNS, and, more broadly, rare diseases. Following Nordic Capital’s initial investment in 2021, Advanz scaled its European presence significantly and built a strong pipeline including innovative rare disease medicines and biosimilars.

Jean-Charles Douin, Senior Managing Director and co-Head of EMEA Private Capital at Ontario Teachers’, said: “Advanz aligns well with our strategy of backing proven management teams in businesses with strong growth potential. With speciality pharmaceuticals a key area of focus for us in healthcare, we look forward to working together with Nordic Capital and the Advanz management team to support its existing and future pipeline, and drive innovation and growth across its global platform.”

Rainer Lenhard, Partner, Nordic Capital Advisors added: “We are excited for Nordic Capital to continue its investment in Advanz together with Ontario Teachers’. This joint investment will support Advanz’s continued development in the years to come and allow the company to continue to scale its business model further and build on the market dynamics in its segment.”

Raj Shah, Partner and Head of Healthcare, Nordic Capital Advisors commented: “During Nordic Capital’s ownership, Advanz has been transformed into a leading European specialty pharma platform by building a best-in-class infrastructure and successfully launching pipeline products during the last few years, enabling future growth in innovative medicines, and a strong track-record of executing on M&A opportunities.”

Steffen Wagner, CEO, Advanz Pharma said: “We are excited to continue our growth journey together with Nordic Capital and Ontario Teachers’. To have them jointly backing our growth ambitions validates our strategy, the capabilities of our team, and increases the positive impact we can deliver for patients.”

Nordic Capital initially invested in Advanz Pharma in 2021 and will now invest via Nordic Capital XI, following the exit of its initial investment through Nordic Capital X.

Terms of the transaction were not disclosed, and the investment is subject to regulatory approvals.

Private Capital at Ontario Teachers’ has over C$60bn of assets globally and uses its deep industry expertise and global network to make control or co-control investments in focus sectors. With a dedicated global healthcare team, Ontario Teachers’ has deployed over C$5bn across 16 healthcare investments in its private capital portfolio, focusing on investments in life sciences, pharmaceutical services, medtech, and healthcare service providers.

Nordic Capital has assets under management of €30bn and invests in selected sectors and companies in Northern Europe and North America, offering partnership, deep sector knowledge, capital and experience to drive sustainable growth. It is one of the most active investors in healthcare globally, focusing on investing in in companies within Medtech, Pharma, Care services and Healthtech. To date, Nordic Capital has made 35 healthcare platform investments and has in total deployed €9.3bn of equity capital in the sector.

Contact Details

Ontario Teachers’
Henrietta Dehn
Email: Henrietta_dehn@otpp.com
Tel: +44 7407 795 960

Kekst CNC
Email: otpp@kcnc.com

Nordic Capital
Katarina Janerud, Communications Manager,
Nordic Capital Advisors
Tel: +46 8 440 50 50
e-mail: katarina.janerud@nordiccapital.com

About Ontario Teachers’ 

Ontario Teachers’ Pension Plan Board (Ontario Teachers’) is a global investor with net assets of $249.8 billion as at June 30, 2023. We invest in more than 50 countries in a broad array of assets including public and private equities, fixed income, credit, commodities, natural resources, infrastructure, real estate and venture growth to deliver retirement income for 336,000 working members and pensioners.

With offices in Toronto, London, Hong Kong, Singapore, Mumbai, San Francisco, New York, Dallas, and São Paulo, our more than 400 investment professionals bring deep expertise in a broad range of sectors and industries. We are a fully funded defined benefit pension plan and have earned an annual total-fund net return of 9.4% since the plan’s founding in 1990. At Ontario Teachers’, we don’t just invest to make a return, we invest to shape a better future for the teachers we serve, the businesses we back, and the world we live in. For more information, visit otpp.com and follow us on LinkedIn.

About Nordic Capital

Nordic Capital is a leading sector-specialised private equity investor with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a long history. Focus sectors are Healthcare, Technology & Payments, Financial Services, and Industrial & Business Services. Key regions are Europe and globally for Healthcare and Technology & Payments investments. Since inception in 1989, Nordic Capital has invested EUR 23 billion in 140 investments. The most recent entities are Nordic Capital XI with EUR 9.0 billion in committed capital and Nordic Capital Evolution with EUR 1.2 billion in committed capital, principally provided by international institutional investors such as pension funds. Nordic Capital Advisors have local offices in Sweden, the UK, the US, Germany, Denmark, Finland, Norway, and South Korea. For further information about Nordic Capital, please visit www.nordiccapital.com.

“Nordic Capital” refers to, depending on the context, any, or all, Nordic Capital branded entities, vehicles, structures, and associated entities. The general partners and/or delegated portfolio managers of Nordic Capital’s entities and vehicles are advised by several non-discretionary sub-advisory entities, any or all of which are referred to as “Nordic Capital Advisors”.

About Advanz Pharma

Advanz Pharma is a global pharmaceutical company with the purpose to improve patients’ lives by providing and enhancing the specialty, hospital, and rare disease medicines they depend on. Our headquarters are in London, UK. We have commercial sales in more than 90 countries globally and have a direct commercial presence in more than 20 countries, including key countries in Europe, the US, Canada, and Australia, a Centre of Excellence in Mumbai, India, as well as an established global distribution and commercialisation partner network. Advanz’s product portfolio and pipeline comprise innovative medicines, specialty generics & biosimilars, and originator brands. Our products cover a broad range of therapeutic areas, including hepatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and, more broadly, rare disease medicines. Our ambition is to be a partner of choice for the commercialisation of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia. In line with our ambition, we are partnering with biopharma and development companies to bring medicines to patients. We can only achieve this due to our dedicated and highly qualified employees, acting in line with our company values of entrepreneurship, speed, and integrity. For more information, please visit https://www.advanzpharma.com

• Investment will accelerate IntegriChain’s ambitious growth targets and cement its status as a leading platform for pharma manufacturers to bring their science to market 
• Further strengthens Nordic Capital’s record as a leading healthcare and technology investorNordic Capital has signed an agreement to acquire a majority share in IntegriChain, a leading provider of pharmaceutical technology, data, consulting, and outsourcing solutions designed to improve how life sciences products reach customers. IntegriChain delivers pharma’s only fully integrated platform for commercialization and market access, helping manufacturers bring their science to market while ensuring patients have affordable, timely, and sustainable access to therapy. Nordic Capital is acquiring the majority stake from Accel-KKR, a global software private equity firm, which first invested in IntegriChain in 2016.IntegriChain’s integrated ICyte Platform helps connect the commercial, financial, and operational dimensions of drug access and profitability. ICyte enables pharmaceutical innovators to achieve better commercial outcomes by digitalizing daily and recurring business activities and integrating data and operations across contracting, pricing, channel and distribution, and gross-to-net.

  “IntegriChain has established a significant position over the last 17 years as a leader in access and commercialization for life sciences – helping manufacturers of all size from strategy to operational execution. We are confident that the company will continue its already strong record of growth by helping customers address their most pressing market access challenges as the industry evolves. The fact that IntegriChain supports more than 400 pharmaceutical customers speaks to the quality of the platform, data, and services they provide. We’re certain that Nordic Capital’s experience supporting companies with similar ambitions, our extensive industry networks, and deep-sector knowledge will take the company to even greater heights,” said Daniel Berglund, Co-Head of Healthcare, Nordic Capital Investment Advisors.

  Josh Halpern, Co-Founder and CEO of IntegriChain, said: “We’re pleased to have Nordic Capital as a new partner to support us on our journey. We are immensely proud of the team at IntegriChain and how we help pharma manufacturers deliver winning commercialization strategies while optimizing their net revenue. With Nordic Capital’s invaluable healthcare and technology experience and expertise, I’m confident that this partnership will enable us to extend our position as a leading platform for pharma manufacturers to bring their science to market. We thank Accel-KKR for their many years of sound guidance and support to help us ready IntegriChain for this important next phase of our business development.”

  The terms of the transaction were not disclosed. Completion of the transaction is expected before year end and is subject to customary closing conditions, including relevant regulatory approvals.

  Morgan Stanley & Co. LLC and Harris Williams LLC are acting as financial advisors to IntegriChain. Evercore is acting as financial advisor to Nordic Capital.

  
  Media contacts:

  Nordic Capital
  Katarina Janerud
  Communications Manager, Nordic Capital Advisors
  Tel: +46 8 440 50 50
  e-mail: katarina.janerud@nordiccapital.com

  IntegriChain
  Jennifer Guinan
  Sage Strategic Marketing
  +1 610.425.8659
  jennifer@sagestrat.com

  
  About IntegriChain
  IntegriChain helps pharma manufacturers bring their science to market, ensuring patients have affordable, timely, and sustainable access to therapy. IntegriChain delivers Pharma’s only data-driven commercialization platform — from strategy to operational execution. The Company’s unique focus on data, technology, consulting, and outsourcing helps connect the commercial, financial, and operational dimensions of drug access and profitability. Through the ICyte Platform, IntegriChain enables pharmaceutical innovators to achieve better commercial outcomes by digitalizing daily and recurring business activities and by integrating data and operations across contracting, pricing, channel and distribution, and gross-to-net. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm, and is headquartered in Philadelphia, PA, with offices in Ambler, PA, and Pune, India. For more information, visit www.integrichain.com or follow on LinkedIn.

  
  About Nordic Capital

  Nordic Capital is a leading private equity investor with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a long history. Focus sectors are Healthcare, Technology & Payments, Financial Services, and selectively, Industrial & Business Services. Key regions are Europe and globally for Healthcare and Technology & Payments investments. Since inception in 1989, Nordic Capital has invested EUR 23 billion in 140 investments. The most recent entities are Nordic Capital XI with EUR 9.0 billion in committed capital and Nordic Capital Evolution with EUR 1.2 billion in committed capital, principally provided by international institutional investors such as pension funds. Nordic Capital Advisors have local offices in Sweden, the UK, the US, Germany, Denmark, Finland, Norway, and South Korea. For further information about Nordic Capital, please visit www.nordiccapital.com.

  “Nordic Capital” refers to, depending on the context, any, or all, Nordic Capital branded entities, vehicles, structures, and associated entities. The general partners and/or delegated portfolio managers of Nordic Capital’s entities and vehicles are advised by several non-discretionary sub-advisory entities, any or all of which are referred to as “Nordic Capital Advisors”

   

  About Accel-KKR

  Accel-KKR is a technology-focused investment firm with $19 billion in cumulative capital commitments. The firm focuses on software and tech-enabled businesses, well-positioned for top-line and bottom-line growth. At the core of Accel-KKR’s investment strategy is a commitment to developing strong partnerships with the management teams of its portfolio companies and a focus on building value alongside management by leveraging the significant resources available through the Accel-KKR network. Accel-KKR focuses on middle-market companies and provides a broad range of capital solutions, including buyout capital, minority-growth investments, and credit alternatives. Accel-KKR also invests across various transaction types, including private company recapitalizations, divisional carve-outs, and going-private transactions. Accel-KKR’s headquarters is in Menlo Park, with offices in Atlanta, London, and Mexico City. Visit accel-kkr.com to learn more.

WOBURN, MA – Azurity Pharmaceuticals, Inc. (“Azurity”) is pleased to announce the closing of its acquisition of Slayback Pharma LLC (“Slayback”) today from existing investors including KKR, a leading global investment firm, and Everstone Capital. Slayback is now a wholly-owned subsidiary of Azurity.

The acquisition brings together companies with complementary strengths, enhancing Azurity’s ability to realize its purpose of Serving Overlooked Patients. The combined development portfolios are expected to yield a significant number of new medicine launches over the coming years.

Azurity leverages its integrated capabilities and vast partner network to continually expand its broad commercial product portfolio and robust pipeline. The company’s patient-centric approach is evident in its diverse array of products catering to various medical needs, including cardiovascular, central nervous system, endocrinological, gastrointestinal, anti-infectives and oncology. Many of Azurity’s medicines are dose-form innovations for patients with needs that are not met by other commercially available therapies.

“I am delighted to announce this combination and the increased potential it brings to do more for overlooked patients,” said Richard Blackburn, CEO of Azurity. “The complementary expertise of the two companies in developing innovative dose forms will result in a strong pipeline of new medicines to meet the needs of patients. We will bring the commercial expertise of Azurity to Slayback’s pipeline and look forward to introducing an even wider range of dose-forms and formulations to meet a broader set of patient needs.”

“The combination of Slayback and Azurity is a union of highly complementary capabilities: Azurity’s innovative commercial acumen and Slayback’s exceptional R&D platform. I am proud of Slayback’s team, our track record of developing complex products with unmatched speed at scale, and the rich history we have built together. I am delighted to join forces with Azurity to help forge a combined entity that is truly one of a kind” added Ajay Singh, Founder and CEO of Slayback.

“We are pleased to add Slayback’s complementary product pipeline and robust R&D capabilities to Azurity. The acquisition of Slayback accelerates Azurity’s strategic growth plan and enhances our ability to launch multiple innovative new drug products into the market every year to serve overlooked patients,” said Jeff Edwards, Partner at QHP Capital, the majority owner of Azurity.

“We have enjoyed working closely with Ajay and Slayback’s impressive management team to scale and support the platform as a leading provider of complex pharmaceuticals,” said Ali Satvat, Partner and Global Head of Health Care Strategic Growth at KKR. “Together we have established an extensive pipeline that Azurity will further build upon, helping to increase accessibility to health care for patients.”

Greenhill & Co. served as financial advisor and White & Case served as legal advisor to Azurity.  Leerink Partners served as lead financial advisor and Raymond James as co-advisor to Slayback while Kirkland & Ellis served as legal advisor to Slayback.

About Azurity Pharmaceuticals:

Azurity is a privately-held pharmaceutical company specializing in providing innovative, high-quality medicines that serve overlooked patients. Azurity supplies a large number of products to treat a wide range of medical conditions. These include cardiovascular, central nervous system, endocrine, gastro-intestinal, anti-infective and oncology medicines. Many of Azurity’s medicines are dose-form innovations for patients with needs that are not met by other available products. Azurity’s medicines have benefited millions of people. For more information, please visit www.azurity.com.

About QHP Capital:

QHP Capital is an investor in technology and services companies in the life sciences and healthcare sectors. QHP traces its heritage back to Quintiles (now IQVIA) and NovaQuest Capital Management. QHP has built an investment platform to provide strategic capital and industry expertise in partnership with strong management teams. The investment team consists of seasoned investment and operational professionals with significant investment experience and deep life science and healthcare expertise. QHP benefits from an extensive network of industry experts and relationships that assist in identifying, analyzing, and growing QHP’s portfolio companies. QHP also manages the NovaQuest Private Equity funds. For more information, please visit www.qhpcapital.com.

Contacts:

For Azurity Pharmaceuticals
Ronald L. Scarboro
rscarboro@azurity.com

<< Back to Press Releases